Schwartzentruber D J
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Immunother. 2001 Jul-Aug;24(4):287-93. doi: 10.1097/00002371-200107000-00004.
High-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer in 15% to 17% of patients with melanoma and renal cell carcinoma. Durable complete regression of all metastases is seen in 6% to 8% of patients. Based on these findings, the U.S. Food and Drug Administration has approved the use of high-dose IL-2 for the treatment of patients with metastatic melanoma and renal cell carcinoma. Interleukin-2 administration is associated with many different side effects, and after many years of use, clinicians have learned how to safely administer high-dose IL-2. This article details practical guidelines for the safe administration of high-dose IL-2.
大剂量白细胞介素-2（IL-2）可使15%至17%的黑色素瘤和肾细胞癌患者出现转移性癌症的客观临床消退。6%至8%的患者所有转移灶实现持久完全消退。基于这些发现，美国食品药品监督管理局已批准使用大剂量IL-2治疗转移性黑色素瘤和肾细胞癌患者。白细胞介素-2给药会引发多种不同的副作用，经过多年使用，临床医生已学会如何安全地给予大剂量IL-2。本文详细介绍了安全给予大剂量IL-2的实用指南。
